A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

This study is a medical research project looking at a new drug called AZD1390. It's specifically for people who have certain types of brain cancer. The main idea is to see how this new drug works when given together with radiation therapy, which is a common cancer treatment. Because this is the first time AZD1390 is being given to people, the most important goal of this study is to find out if it's safe to use and how well people can tolerate it. The researchers also want to understand how the drug moves through the body – how it's absorbed, distributed, and eventually leaves the body.

The study is split into different groups, called 'arms,' and each group is designed to learn something specific. For example, some groups might have patients with glioblastoma that has come back, while others might have patients with a newly diagnosed glioblastoma. Each group will receive AZD1390 along with a different type or schedule of radiation therapy, which is already a standard treatment for their specific condition. By testing different doses of AZD1390 and combining it with various radiation plans, doctors hope to find the safest and most effective ways to use this new drug.

This kind of study, called a Phase 1 study, is a crucial early step in developing new medicines. It helps doctors learn important information about a new drug's safety before it can be studied in more people to see how well it treats the cancer. It's all about gathering vital information meticulously to make sure any new treatment is as safe and helpful as possible for future patients.